Retrospective
NRG Clinico-Transcriptomic Risk Stratification (Abstract 5000)
ForNCCN β₯ high-risk localized prostate cancer, RT+ADT candidates
TL;DR22-gene GC independently predicts MFS, DM, and OS; combined NRG score reclassifies ~25% discordant NCCN high-risk pts for AAP intensification.
- STAMPEDE MO calibration anchor (Attard, Lancet 2022): HRMFS 0.53 (95% CI 0.44-0.64), HROS 0.60 (0.48-0.73), both p < 0.0001 for AAP intensification
+1 more figure
| GC High | GC Low | |
|---|---|---|
| Clinical High | 49% | 15% |
| Clinical Low | 9% | 27% |
5 details
- π Combined clinico-transcriptomic (CT) score: NCCN points + GC points
- NCCN HR = 1 pt; NCCN VHR = 2 pts
- GC <HR = 0 pt; GC HR = 1 pt; GC VHR = 2 pts
- CT HR (β€2 pts) β RT+ADT; CT VHR (β₯3 pts) β RT+ADT+AAP
- π 22-gene GC independently predicts MFS, DM, and OS beyond clinical variables alone (p < 0.001 for each endpoint)
- π ~25% of NCCN β₯HR pts have discordant clinical vs. GC risk, warranting the combined approach
- β οΈ Framework developed on existing NRG trial data; no prospective RCT validating CT-score-guided treatment allocation reported
- β οΈ Design not fully specified in source; likely secondary correlative analysis; GC cutoffs extend Spratt et al. (JCO 2018) prior work
- Prospective RCT: does CT-score-guided allocation improve outcomes vs. clinical risk alone?
- Generalizability to modern ARSI-backbone ADT regimens
- GC threshold stability across contemporary cohorts
π Sources Β· π¦ 2 tweets
#ASCO26 GU Oncology Spotlight π¨
— Dra. MarΓa Natalia Gandur Quiroga (@nataliagandur) May 30, 2026
π¬ Abstract 5000 | High-risk prostate cancer
Clinico-transcriptomic risk stratification to guide abiraterone intensification
Presented by Krishnan R. Patel, MD, MHS@Krishnan_Patel@OncoAlert@ASCO
In high-risk localized prostate cancer,β¦ pic.twitter.com/pZSCiTyGB8
#ASCO26 Dr. Patel presented a clinically practical framework integrating NCCN clinical risk + a 22-gene genomic classifier to guide treatment intensification in high-risk localized prostate cancer.
— Julian Chavarriaga (@chavarriagaj) May 30, 2026
Key findings:
πΉ The genomic classifier independently improved prognosticβ¦ pic.twitter.com/fRcdTmfBec
Proton vs Photon PMRT Capsular Contracture (Zerey et al.)
ForPost-mastectomy breast cancer, subpectoral TE/I or DTI reconstruction, PMRT cand
TL;DRMVA HR 1.76 (P=0.083) proton vs photon CC, non-significant; proton+DTI 2yr CC 50% vs photon+DTI 35%.
- Proton PMRT improves cardiac/pulmonary dosimetry vs photon; this CC signal is the risk to weigh in reconstruction planning
8 details
- π Retrospective, 2 centers/single institution, N=175 (89 proton, 86 photon), Jan 2017-Dec 2023; median f/u 42 vs 47 mo
- π 2-year CC rates by modality and reconstruction type
Reconstruction Proton Photon DTI 50% 35% TE/I 23% 12% - π MVA HR 1.76 (95% CI 0.93-3.32), P=0.083 for proton vs photon
- π Univariate HR 2.3 (95% CI 1.26-4.30), P=0.007 for proton vs photon
- π DTI vs TE/I in MVA: HR 3.0 (95% CI 1.7-5.5), P<.001
- β οΈ Groups unbalanced for reconstruction type (TE/I vs DTI, P<.001); this is the dominant confounder and MVA adjustment may be insufficient
- β οΈ Groups also unbalanced for tumor laterality (P<.001); uncontrolled institutional practice patterns, not randomization
- β οΈ MVA primary result is P=0.083, below conventional significance; framed as a trend, not a confirmed signal
- Does proton-CC signal replicate in a prospective matched or randomized cohort?
- Optimal reconstruction type (TE/I vs DTI) when proton PMRT is indicated for cardiac/pulmonary dosimetry reasons?
π Sources Β· π 2 papers
Abstract
Bladder-preserving TMT for MIBC: prognostic factors (ESTRO 2026)
ForcT2-T4aNOMO MIBC, median age 76, selected for organ-preserving TMT
TL;DRCLR 63.7% in 369 MIBC pts on TMT; 5-FU-based CRT (OR 4.9) and portal imaging frequency independently predicted CLR.
- CLR 63.7% and salvage cystectomy 9.7% consistent with published international TMT series
8 details
- π Multicenter retrospective cohort, Spain 2010-2022; N=369, median age 76, 85% male, cT2-T4aNOMO
- π TMT = maximal TURBT + concurrent chemoradiotherapy; 1Β° EP: CLR; multivariable logistic regression
- π CLR: 63.7%; salvage cystectomy: 9.7%
- π Disease progression 28.8%: local 10.1%, systemic 10.7%, combined 8.7%
- π CLR associated with lower local recurrence and better survival (no OS/CSS HR in source)
- π Independent predictors of CLR (multivariable)
- 5-FU-based CRT β higher CLR: OR 4.9 (95% CI 1.1-22.1), p=0.038
- Weekly portal imaging β lower CLR: OR 0.35 (95% CI 0.20-0.60), p<0.001
- β οΈ Retrospective, 12-yr accrual (2010-2022): era effects likely across RT technique and CRT regimen selection
- β οΈ Portal imaging OR 0.35 is counterintuitive; probably proxies older/less precise RT delivery, not a causal detriment
- 5-FU vs gemcitabine vs other radiosensitizers: prospective CRT regimen comparison needed
- Whether modern IGRT (VMAT, CBCT) improves CLR vs older portal imaging techniques
π Sources Β· π¦ 1 tweet
π’ Presentamos en #ESTRO26 nuestro anΓ‘lisis multicΓ©ntrico sobre preservaciΓ³n vesical en cΓ‘ncer vesical mΓΊsculo-invasivo tratado con TMT.
— URONCOR (@URONCOR) May 19, 2026
π En 369 pacientes, la respuesta completa clΓnica se asociΓ³ a menor recurrencia local y mejor supervivencia!@fcounago #NicoFeltes pic.twitter.com/aQjjkcHGP4